Information Provided By: 
Fly News Breaks for June 26, 2017
MMSI
Jun 26, 2017 | 06:13 EDT
Piper Jaffray analyst Matt O'Brien believes Merit Medical Systems' recent approval to treat benign prostatic hyperplasia could become a meaningful revenue contributor. Benign prostatic hyperplasia is a condition that affects urination in approximately 35M men in the U.S. and 800M around the world, the analyst tells investors in a research note. He continues to recommend building positions in Merit Medical. O'Brien has an Overweight rating on the shares with a $39 price target.
News For MMSI From the Last 2 Days
There are no results for your query MMSI
